{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-331369","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2021-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.199440+00:00","generated_at":"2026-06-28T07:47:45.626995+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roche terminates license agreement for AT-527 with Atea; effective Feb 10, 2022","bullets":["Roche sent termination notice on Nov 12, 2021; license ends Feb 10, 2022.","Agreement covered ex-U.S. rights to develop and commercialize AT-527.","No early termination penalties will be incurred by Atea.","Atea retains full rights to AT-527 outside the terminated pact."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-331369","json":"https://secwatch.observer/filing/0001193125-21-331369.json","markdown":"https://secwatch.observer/filing/0001193125-21-331369.md","text":"https://secwatch.observer/filing/0001193125-21-331369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312521331369/0001193125-21-331369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312521331369/d368899d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T07:47:45.626995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}